Theme Member
Dr Liu Lu

Contact

Phone: 08 812 84319

Email: liu.lu@sahmri.com

Qualifications

PhD (Medicine), The University of Adelaide

Bachelor of Health Science (Hons), The University of Adelaide

Research Focus

Currently approved tyrosine kinase inhibitors (TKIs; imatinib, nilotinib and dasatinib) are the main course of treatment for chronic myeloid leukaemia (CML). However, diverse TKI resistance mechanisms cause a proportion of patients to fail therapy. Identified resistance mechanisms in CML patients include Bcr-Abl kinase domain mutations, increasedBCR-ABL1 expression, and increased drug-efflux or decreased drug-influx. Ponatinib, a novel third generation TKI, has recently been demonstrated to successfully overcome mutation-based, especially T315I-based, resistance in a cellular screen. Dr Lu's study focuses on investigating the cellular transport of ponatinib, which may mediate the development of ponatinib resistance, and identifying other potential ponatinib resistance mechanisms by generating and characterising ponatinib resistant CML cell lines. Dr Liu Lu's study also aims to determine the efficacy of ponatinib in different mutation settings, and therefore facilitates future TKI design.

Awards/Funding

2016 Dean’s Commendation for Doctoral Thesis Excellence

2016 Beat Cancer Project Travel Grant

2015 Runner Up Prize For SAHMRI PhD Presentation

2012 Adelaide Graduate Research Scholarship to support the PhD

2011 Admittance to the Golden Key International Honour’s Society (did not accept)

2010 Faculty of Science Outstanding Academic Achievement Award

2009 School of Molecular & Biomedical Science Summer Research Scholarship

Publications

Jueqiong Wang, Liu Lu, Chung H Kok, Verity A Saunders, Jarrad M Goyne, Phuong Dang, Tamara M Leclercq, Timothy P Hughes, and Deborah L White. 2017. Increased peroxisome proliferator-activated receptor-gamma activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica May;102(5):843-853(I.F: 5.814)

Lu L, Saunders VA, Leclercq TM, Hughes TP, White DL. 2015. Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia. Aug;29(8):1792-4.(I.F: 12.104)

Get in touch
+61 8 8128 4000 info@sahmri.com
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.